AstraZeneca: 'ground-breaking' results for tezepelumab
(CercleFinance.com) - After a phase III trial, AstraZeneca confirmed that tezepelumab has been shown to be effective compared to placebo in patients with severe and uncontrolled asthma.
For Professor Andrew Menzies-Gow, director of the pulmonary division at the Royal Brompton Hospital in London and principal investigator of the trial, the results obtained are "ground-breaking results for the many patients with severe asthma who continue to face debilitating symptoms despite receiving standard of care inhaled medicines and currently approved biologics."
"Tezepelumab has the potential to transform treatment for a broad population of patients with severe asthma regardless of their type of inflammation, including those with and without an eosinophilic phenotype," he added.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
For Professor Andrew Menzies-Gow, director of the pulmonary division at the Royal Brompton Hospital in London and principal investigator of the trial, the results obtained are "ground-breaking results for the many patients with severe asthma who continue to face debilitating symptoms despite receiving standard of care inhaled medicines and currently approved biologics."
"Tezepelumab has the potential to transform treatment for a broad population of patients with severe asthma regardless of their type of inflammation, including those with and without an eosinophilic phenotype," he added.
Copyright (c) 2021 CercleFinance.com. All rights reserved.